Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20240724010
- Term of Validity
- 24 July 2024 - 24 July 2025
- Company's Country
- Germany
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A German university offers a solution to measure antibody avidity in biological samples via an immuno thermal shift assay (ITSA). This helps to evaluate the degree of antibody-antigen interaction and to draw conclusions among others on antibody response. Licenses are offered to companies active in diagnostics.
- Full Description
-
A multitude of seroassays has been developed to detect and quantitate the humoral immune response against infectious agents, vaccines and autoantigens. Antibody quantity only partially reflects functional aspects of antibody responses in vivo. Determination of antibody avidity or functional affinity gives important additional information concerning the strength and breadth of antibody-antigen interactions that allows conclusions on the affinity maturation of the antibody response and time point of antigen contacts.
A German university presents a novel, homogenous seroassay termed ITSA, which detects an increase in the thermostability of the test antigen through antibody binding, thereby enabling the measurement of antibody avidity in biological samples. The results show that ITSA is suited for monitoring the affinity maturation of antibodies in individuals vaccinated against SARS-CoV-2. In addition, the application field may be extended to the serodiagnosis of other pathogens, e.g., EBV, CMV, toxoplasmosis, as well as to patients with autoimmune diseases.
The university offers licenses to in vitro diagnostics manufacturers for medical diagnostics - Advantages and Innovations
- ITSA differs from conventional solid phase immunoassays as it allows direct, precise and rapid measuring of dissociation properties of antigen-antibody complexes in biological samples. Compared to conventional immunoassays, ITSA is processed according to a much simpler protocol, e.g., does not require elaborate washing steps, has no special requirements for laboratory equipment, and offers the possibility for scaling up, automatisation, and miniaturisation while comprising comparable sensitivity and specificity.
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
-
Proof of concept
Patent application filed in Europe.
Partner Sought
- Expected Role of a Partner
-
The university offers license agreements
• Type of partner sought: in vitro diagnostics manufacturer for medical diagnostics
• Role of partner: Make use of the invention as an assay for monitoring immune status in patients after vaccination. The application can be extended to the diagnosis, monitoring and assessment of immune status for various pathogen infections or to patients with autoimmune diseases. - Type and Size of Partner
- SME 11-49
- Big company
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001018 - Virus, Virology/Antibiotics/Bacteriology
- 06001012 - Medical Research
- 06001013 - Medical Technology / Biomedical Engineering
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001002 - In-vitro diagnostics
- Sector Groups Involved
- Health
- Targeted countries
- All countries
